These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1439 related articles for article (PubMed ID: 8690525)

  • 1. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo.
    Jäger E; Ringhoffer M; Dienes HP; Arand M; Karbach J; Jäger D; Ilsemann C; Hagedorn M; Oesch F; Knuth A
    Int J Cancer; 1996 Jul; 67(1):54-62. PubMed ID: 8690525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens.
    Jäeger E; Bernhard H; Romero P; Ringhoffer M; Arand M; Karbach J; Ilsemann C; Hagedorn M; Knuth A
    Int J Cancer; 1996 Apr; 66(2):162-9. PubMed ID: 8603805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
    Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
    Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides.
    Jäger E; Maeurer M; Höhn H; Karbach J; Jäger D; Zidianakis Z; Bakhshandeh-Bath A; Orth J; Neukirch C; Necker A; Reichert TE; Knuth A
    Int J Cancer; 2000 May; 86(4):538-47. PubMed ID: 10797269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals.
    Jäger E; Ringhoffer M; Arand M; Karbach J; Jäger D; Ilsemann C; Hagedorn M; Oesch F; Knuth A
    Melanoma Res; 1996 Dec; 6(6):419-25. PubMed ID: 9013479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
    Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
    Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients.
    Yamasaki S; Okino T; Chakraborty NG; Adkisson WO; Sampieri A; Padula SJ; Mauri F; Mukherji B
    Cancer Immunol Immunother; 1995 Apr; 40(4):268-71. PubMed ID: 7750125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo.
    Oertli D; Marti WR; Zajac P; Noppen C; Kocher T; Padovan E; Adamina M; Schumacher R; Harder F; Heberer M; Spagnoli GC
    Hum Gene Ther; 2002 Mar; 13(4):569-75. PubMed ID: 11874634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
    Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
    J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro.
    Bakker AB; Marland G; de Boer AJ; Huijbens RJ; Danen EH; Adema GJ; Figdor CG
    Cancer Res; 1995 Nov; 55(22):5330-4. PubMed ID: 7585596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
    Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA
    Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.
    Hersey P; Menzies SW; Coventry B; Nguyen T; Farrelly M; Collins S; Hirst D; Johnson H
    Cancer Immunol Immunother; 2005 Mar; 54(3):208-18. PubMed ID: 15449035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
    Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
    J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro.
    Tjandrawan T; Martin DM; Maeurer MJ; Castelli C; Lotze MT; Storkus WJ
    J Immunother; 1998 Mar; 21(2):149-57. PubMed ID: 9551367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.